Month: November 2024

Evolving Challenges in Closed-System Biomanufacturing

By

Reading time: 5 minutes Share this article:     Closed-system biomanufacturing has revolutionized cell and gene therapy production, offering unparalleled sterility and control. However, as the industry advances and regulatory expectations for contamination control increase, new challenges arise that demand innovative solutions. In this blog post, we’ll explore the evolving complexities of closed systems and …

T Cell Cryopreservation Using Exbumin®, Recombinant Human Serum Albumin, and Reduced DMSO

By

Key Points Exbumin®, recombinant human serum albumin (rHSA), demonstrated superior T cell viability, health, and proliferation post-cryopreservation compared to clinical HSA and a 10% DMSO solution. Notably, this was achieved with only 2.5% DMSO, demonstrating Exbumin’s ability to reduce DMSO concentrations without compromising cell health. Exbumin is an approved excipient for therapeutic injection and offers …